Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Renishaw introduces RUO multiplex assay system
Marketing head Jim Greaves said the RUO system launch is a truly transformative technology introduction, in advance of our fully regulated RenDx platform for human diagnostics that is
Marketing head Jim Greaves said the RUO system launch is a truly transformative technology introduction, in advance of our fully regulated RenDx platform for human diagnostics that is
Istodax is indicated for treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. Celgene said that sNDA filing for Istodax
The new patent covers several new quinoxalinyl-piperazine compounds, the process for their preparation, pharmaceutical composition, and a method for their producing an anti-proliferative effect. Additionally, the new patent
Life Technologies’ new Asia Distribution Center (ADC), located in Singapore’s Tuas Biomedical Park, will provide customers with systems, consumables and services that enable researchers to accelerate scientific and
The not approvable letter was previously issued by the FDA to Jerini in 2008 for Firazyr as the treatment for acute attacks of hereditary angioedema (HAE). Firazyr is
The collaboration is expected to enhance the drug development projects and the ongoing Harvard research projects by creating a drug discovery bridge between academia and industry. Under Harvard-UCB
The FDA said Rhucin BLA was not sufficiently complete to enable a critical medical review. Additionally, it also said that thedata provided to the FDA from the previous
As part of an international collaboration reaching from Singapore to California, the scientists examined the DNA of more than 60 people with MSSE and 110 of their unaffected
KUR-023 is delivered from a double barrelled syringe with a mixing spray tip. The product candidate is delivered as a spray which then arrives on the dura as
NerBloc, a botulinum toxin type B neuromuscular-blocking agent, has been approved by the Japanese regulatory authority in 21 January 2011. NerBloc has showed improvement in TWSTRS (Toronto Western